Sliding Peptide Amphiphile Nanofibers for Chronic SCI Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic interventions for spinal cord injury (SCI), particularly in chronic phases, face challenges such as poor survival of transplanted cells, limited half-life of small molecule therapeutics, and ineffective localization, necessitating improved methods for treating SCI.
Innovation Solution
Development of peptide amphiphiles (PAs) with slider peptides that non-covalently interact with a backbone, forming nanofibers to enhance the mobility and bioactivity of biomimetic sequences, targeting inhibitory molecules like CSPGs to promote neuronal growth and recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transplanted cells are directly delivered to the injury site, then cell transplantation therapy is performed, but the cells do not survive or are overcome by the inhibitory landscape
Solution Approach 1:
The patent introduces peptide amphiphile nanofibers as an intermediary delivery system that carries therapeutic peptides to the injury site. These nanofibers serve as a mediator between the therapeutic agent and the inhibitory landscape, enabling controlled release and protection of the therapeutic peptides from the hostile environment, thereby improving cell survival and therapeutic efficacy
Solution Approach 2:
The patent creates composite therapeutic systems combining peptide amphiphiles with bioactive sequences (such as CSPG-binding peptides and neuronal growth-promoting sequences). This composite approach integrates multiple therapeutic functions into a single delivery system, allowing simultaneous inhibition of the inhibitory landscape and promotion of neuronal regeneration
2Duration of action of moving object
If small molecule and growth factor therapeutics are used, then therapeutic delivery is achieved, but they are limited by short half-life and poor localization
Solution Approach 1:
The peptide amphiphile nanofiber system provides continuous therapeutic action through sustained release of bioactive peptides. The nanofibers maintain structural integrity over extended periods, continuously presenting therapeutic sequences to target cells and the inhibitory landscape, thereby eliminating the short half-life limitation of small molecule therapeutics
Solution Approach 2:
The patent designs the nanofiber system to concentrate therapeutic peptides specifically at the injury site with high local concentration. The nanofibers are engineered to bind selectively to CSPGs at the injury interface, creating a localized therapeutic reservoir that maximizes treatment efficacy while minimizing systemic distribution, thereby achieving superior localization compared to small molecule delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PA-slider systems effectively inhibit CSPG inhibition, enhance neuronal growth and recovery, and improve synaptic plasticity, demonstrating potential for treating chronic spinal cord injuries.
Implementation Method 1
the charged sequence interacts non-covalently with the charged peptide segment of the PA. In some embodiments, the charged sequence interacts electrostatically with the charged peptide segment
Implementation Method 2
a plurality of PAs assemble to form a nanofiber
Data Source
AI summary
Provided herein are systems including a peptide amphiphile backbone and a peptide that interacts non-covalently with the peptide amphiphile. The peptide is able to move or slide along the surface of the PA, and is therefore referred to as a “slider”. Interaction of the slider with the PA backbone improves bioactivity, stability, and prevents the slider against degradation.